Effect of ranolazine on Tp-e interval, Tp-e/QTc, and P-wave dispersion in patients with stable coronary artery disease.
P‐wave dispersion
Tp‐e interval
coronary artery disease
index of cardiac electrophysiological balance (iCEB)
ranolazine
Journal
Journal of arrhythmia
ISSN: 1880-4276
Titre abrégé: J Arrhythm
Pays: Japan
ID NLM: 101263026
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
08
01
2021
revised:
28
03
2021
accepted:
14
04
2021
entrez:
13
8
2021
pubmed:
14
8
2021
medline:
14
8
2021
Statut:
epublish
Résumé
Ranolazine is an antianginal drug and also exhibits antiarrhythmic effect by affecting action potential time, refractory period, and repolarization reserve. We evaluated the effect of ranolazine therapy on myocardial repolarization parameters (Tp-e, QT, QTc intervals, Tp-e/QT, and Tp-e/QTc ratios), index of cardiac electrophysiological balance (iCEB) (QT/QRS, QTc/QRS) and P-wave dispersion (PWD) in patients with stable coronary artery disease (CAD). This study included 175 patients, aged between 35 and 90 years who were followed with stable CAD for at least 3 months. Ninety patients had been receiving ranolazine for at least 1 month, and 85 patients had never received ranolazine. All patients' basic demographic data, risk factors, medications, and echocardiographic parameters recorded. Myocardial repolarization parameters, P-wave times, and PWD were analyzed from 12 lead electrodes. There was no variation between the groups in terms of basic demographic parameters and CAD risk factors. Tp-e interval (87.3 ± 14.4 vs. 90.8 ± 12.4 msn, Tp-e/QTc ratio, QTc, P
Identifiants
pubmed: 34386127
doi: 10.1002/joa3.12549
pii: JOA312549
pmc: PMC8339098
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1015-1022Informations de copyright
© 2021 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society.
Déclaration de conflit d'intérêts
The authors declare that they have no potential conflicts of interest concerning the research, authorship, and publication of this article.
Références
Circulation. 2006 May 23;113(20):2462-72
pubmed: 16717165
JAMA. 2004 Jan 21;291(3):309-16
pubmed: 14734593
Circulation. 2004 Aug 24;110(8):904-10
pubmed: 15302796
J Electrocardiol. 2018 Nov - Dec;51(6):1077-1083
pubmed: 30497734
Europace. 2013 Mar;15(3):317-24
pubmed: 23220484
J Am Coll Cardiol. 2018 Aug 7;72(6):636-645
pubmed: 30071993
Europace. 2017 May 1;19(5):712-721
pubmed: 27702850
Ann Noninvasive Electrocardiol. 2015 Nov;20(6):592-600
pubmed: 25631523
J Electrocardiol. 2008 Nov-Dec;41(6):567-74
pubmed: 18790499
Int J Cardiol. 2017 Dec 15;249:61-65
pubmed: 29121758
Indian Pacing Electrophysiol J. 2016 Jul - Aug;16(4):126-133
pubmed: 27924760
J Electrocardiol. 2018 Dec 6;53:36-39
pubmed: 30721839
J Cardiovasc Med (Hagerstown). 2014 Mar;15(3):254-9
pubmed: 24662415
Europace. 2014 Jul;16(7):973-9
pubmed: 24473502
J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63
pubmed: 16376782
Ann Noninvasive Electrocardiol. 2015 Jan;20(1):53-61
pubmed: 24934391
Ann Noninvasive Electrocardiol. 2016 May;21(3):294-304
pubmed: 26305685
J Electrocardiol. 2019 Mar - Apr;53:52-56
pubmed: 30616002
J Cardiovasc Pharmacol Ther. 2011 Jun;16(2):168-72
pubmed: 20924097
J Electrocardiol. 2018 Nov - Dec;51(6):929-933
pubmed: 30497749
Ann Noninvasive Electrocardiol. 2018 Jan;23(1):
pubmed: 28653394
Circulation. 2018 Oct 23;138(17):1879-1896
pubmed: 30354657
Pacing Clin Electrophysiol. 2016 Sep;39(9):1006-15
pubmed: 27358212
JRSM Cardiovasc Dis. 2016 Mar 21;5:2048004016639443
pubmed: 27081484
Heart Rhythm. 2005 Feb;2(2):162-9
pubmed: 15851290
Clin Cardiol. 2001 Oct;24(10):676-80
pubmed: 11596617
Europace. 2012 Jun;14(6):877-81
pubmed: 22186777
Ann Noninvasive Electrocardiol. 2001 Apr;6(2):159-65
pubmed: 11333174
Pacing Clin Electrophysiol. 2012 Mar;35(3):302-7
pubmed: 22229482
JAMA. 2007 Apr 25;297(16):1775-83
pubmed: 17456819